US and EU exposure to EDCs: disease burden and cost analysis

Endocrine-disrupting chemicals (EDCs) contribute to disease and dysfunction and incur high associated costs. Exposure to EDCs varies widely between the USA and Europe because of differences in regulations and, therefore, the researchers aimed to quantify disease burdens and related economic costs to allow comparison.
According to the study, the disease costs of EDCs were much higher in the USA than in Europe ($340 billion [2·33% of GDP] vs $217 billion [1·28%]). Differences from the European Union suggest the need for improved screening for chemical disruption to endocrine systems and proactive prevention (The Lancet Diabetes & Endocrinology, 17 October 2016).
Click here for an abstract of the article.
Click here for an article about the research by NYU.

This news item is also included in our monthly overview, the NVC Members-only Update. If you have any questions, please contact us: info@nvc.nl, +31-(0)182-512411.